Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analyst sentiment is moderately bullish: Sixteen analysts give Compass Therapeutics an average “Moderate Buy” rating, with 13 buys, one strong buy, one hold, and one sell. The average 12-month price target is $11.77.
• Institutional ownership remains substantial: Institutional investors hold 68.43% of CMPX shares, with several firms recently initiating or increasing positions.
• Shares and earnings remain under pressure: CMPX opened at $2.25, down 0.4%, while the company reported a quarterly loss of $0.13 per share versus the $0.11 consensus loss estimate.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has received an average recommendation of "Moderate Buy" from the sixteen research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $11.7692.

CMPX has been the topic of several research reports. Piper Sandler boosted their price objective on shares of Compass Therapeutics from $4.00 to $6.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Stifel Nicolaus set a $6.00 target price on shares of Compass Therapeutics in a research note on Monday, June 1st. Citigroup reissued a "market outperform" rating on shares of Compass Therapeutics in a research report on Thursday, June 4th. Wall Street Zen lowered Compass Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 8th. Finally, Citizens Jmp reaffirmed a "market outperform" rating and issued a $10.00 price target on shares of Compass Therapeutics in a report on Tuesday, April 28th.

Institutional Trading of Compass Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CMPX. Parallel Advisors LLC acquired a new position in shares of Compass Therapeutics in the first quarter valued at $28,000. Russell Investments Group Ltd. boosted its stake in Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company's stock worth $27,000 after buying an additional 7,592 shares in the last quarter. Xponance LLC acquired a new stake in Compass Therapeutics during the fourth quarter worth $55,000. CIBC Bancorp USA Inc. bought a new stake in Compass Therapeutics in the 3rd quarter valued at $37,000. Finally, PNC Financial Services Group Inc. increased its holdings in Compass Therapeutics by 2,572.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 11,038 shares of the company's stock valued at $58,000 after buying an additional 10,625 shares during the period. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Trading Down 0.4%

Shares of CMPX stock opened at $2.25 on Friday. Compass Therapeutics has a 1 year low of $1.61 and a 1 year high of $6.88. The firm's fifty day simple moving average is $2.11 and its 200 day simple moving average is $3.74. The firm has a market capitalization of $405.20 million, a P/E ratio of -5.62 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities research analysts anticipate that Compass Therapeutics will post -0.46 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source